Tarsus Pharmaceuticals Inc (NASDAQ:TARS) price on Friday, January 17, fall -0.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $46.52.
A look at the stock’s price movement, the close in the last trading session was $46.92, moving within a range at $46.05 and $47.51. Turning to its 52-week performance, $57.14 and $20.08 were the 52-week high and 52-week low respectively. Overall, TARS moved -10.07% over the past month.
Tarsus Pharmaceuticals Inc’s market cap currently stands at around $1.78 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 58.02M for the company’s revenue for the quarter, with a low and high estimate of 55.2M and 61.56M respectively. The average forecast suggests up to a 343.73% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 174.69M, representing a 901.25% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TARS is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend TARS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TARS’s current price about -11.12% and -7.73% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.06, while 7-day volatility ratio is 6.51% and 5.41% in the 30-day chart. Further, Tarsus Pharmaceuticals Inc (TARS) has a beta value of 1.03, and an average true range (ATR) of 2.82. Analysts have given the company’s stock an average 52-week price target of $63, forecast between a low of $63 and high of $63. Looking at the price targets, the low is -35.43% off current price level while to achieve the yearly target high, price needs to move -35.43%. Nonetheless, investors will most likely welcome a -35.43% jump to $63 which is the analysts’ median price.
If we refocus on Tarsus Pharmaceuticals Inc (NASDAQ:TARS), historical trading data shows that trading volumes averaged 0.95 over the past 10 days and 768.83K over the past 3 months. The company’s latest data on shares outstanding shows there are 38.20 million shares.
The 14.76% of Tarsus Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 109.01% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.33 million on 2024-12-31, giving us a short ratio of 14.07. The data shows that as of 2024-12-31 short interest in Tarsus Pharmaceuticals Inc (TARS) stood at 1987.0001000000002 of shares outstanding, with shares short rising to 7.18 million registered in 2024-11-29. Current price change has pushed the stock -15.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TARS stock continues to rise going into the next quarter.
